weight loss injection retatrutide Results:Trial Data and FDA Status Phase III retatrutide study demonstrates

What is BPC-157

Because of this, the medication stays in the bloodstream for a long time, meaning people only need to take it once a week for it to work

These treatments are not appropriate for all patients and may be contraindicated in individuals with certain medical conditions including hormone-sensitive cancers, blood clotting disorders, severe liver disease, or cardiovascular conditions

Research from ACR Convergence 2025 highlighted GLP-1 receptor agonists as showing particular promise in psoriatic arthritis management, where the dual burden of skin and joint disease creates challenges for conventional therapies